Back to School: How biopharma can reboot drug development. Access exclusive analysis here

BTGC becomes an earnings story

BTGC becomes an earnings story

Bio-Technology General Corp. said it has turned the corner to profitability. The company reported its first profitable operating period, for the quarter ended March 31, with product sales of $5.2 million and net income of $402,000 ($0.01).

"The critical thing," said William Pursley, newly appointed senior vice president of marketing, sales and commercial development, "is that the company

Read the full 626 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers